Cycrimine
Pagitane (cycrimine) is a small molecule pharmaceutical. Cycrimine was first approved as Pagitane on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cycrimine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PAGITANE | Eli Lilly | N-008951 DISCN | 1982-01-01 | 2 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
110 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 5 | 4 | 2 | 3 | 11 |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | — | 4 | 2 | 2 | 3 | 11 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 2 | 1 | 3 | 4 | 1 | 10 |
| Social phobia | D000072861 | EFO_1001917 | F40.1 | 1 | 2 | 1 | 1 | — | 5 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 1 | 1 | 1 | 1 | — | 4 |
| Multidrug-resistant tuberculosis | D018088 | EFO_0007381 | — | — | — | 1 | 1 | 2 | |
| Psychotic disorders | D011618 | F20.81 | — | 1 | 1 | 1 | — | 2 | |
| Prostatitis | D011472 | EFO_0003830 | N41 | — | — | — | 1 | — | 1 |
| Treatment-resistant depressive disorder | D061218 | — | — | — | 1 | — | 1 | ||
| Spinal cord injuries | D013119 | EFO_1001919 | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Panic disorder | D016584 | EFO_0004262 | F41.0 | 1 | 1 | 1 | — | 1 | 4 |
| Pain | D010146 | EFO_0003843 | R52 | — | 2 | 1 | — | — | 3 |
| Autistic disorder | D001321 | EFO_0003758 | F84.0 | — | — | 3 | — | — | 3 |
| Phobic disorders | D010698 | EFO_1001908 | F40 | — | 2 | 1 | — | — | 3 |
| Smoking cessation | D016540 | EFO_0004319 | — | 1 | 1 | — | — | 2 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | 1 | — | — | 1 |
| Asperger syndrome | D020817 | EFO_0003757 | F84.5 | — | — | 1 | — | — | 1 |
| Pervasive child development disorders | D002659 | EFO_0003756 | F84 | — | — | 1 | — | — | 1 |
| Alcohol drinking | D000428 | EFO_0004329 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 2 | 4 | — | — | — | 6 |
| Cocaine-related disorders | D019970 | F14 | — | 3 | — | — | 1 | 4 | |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | 1 | — | — | — | 2 |
| Traumatic brain injuries | D000070642 | S06 | 1 | 1 | — | — | — | 2 | |
| Low back pain | D017116 | HP_0003419 | M54.5 | — | 2 | — | — | — | 2 |
| Motor activity | D009043 | EFO_0003940 | 1 | 1 | — | — | — | 2 | |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 2 | — | — | — | 2 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 1 | — | — | — | 1 |
| Cigarette smoking | D000073865 | — | 1 | — | — | — | 1 | ||
| Agoraphobia | D000379 | EFO_1001872 | F40.0 | — | 1 | — | — | — | 1 |
Show 5 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tobacco use disorder | D014029 | F17 | 2 | — | — | — | — | 2 | |
| Tourette syndrome | D005879 | EFO_0004895 | F95.2 | 1 | — | — | — | 1 | 2 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 1 | — | — | — | — | 1 |
| Sleep apnea syndromes | D012891 | EFO_0003877 | G47.3 | 1 | — | — | — | — | 1 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | — | — | — | — | 1 |
| Body dysmorphic disorders | D057215 | F45.22 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | — | 2 | 2 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | — | — | — | 2 | 2 |
| Chronic pain | D059350 | HP_0012532 | — | — | — | — | 2 | 2 | |
| Healthy volunteers/patients | — | — | — | — | — | 2 | 2 | ||
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | — | — | — | 2 | 2 |
| Liver transplantation | D016031 | EFO_0010682 | — | — | — | — | 1 | 1 | |
| Smoking | D012907 | EFO_0003768 | F17 | — | — | — | — | 1 | 1 |
| Acrodynia | D000170 | EFO_1001756 | — | — | — | — | 1 | 1 | |
| Post-lyme disease syndrome | D000077342 | — | — | — | — | 1 | 1 | ||
| Psychological trauma | D000067073 | — | — | — | — | 1 | 1 |
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CYCRIMINE |
| INN | cycrimine |
| Description | Cycrimine is a member of the class of piperidines that is 3-(piperidin-1-yl)propan-1-ol in which one of the hydrogen atoms at the 1-position is substituted by cyclopentyl, and the other is substituted by phenyl. A central anticholinergic, it is used as its hydrochloride salt in the management and treatment of Parkinson's disease. It has a role as an antiparkinson drug, a muscarinic antagonist and an antidyskinesia agent. It is a tertiary alcohol, a member of piperidines and a tertiary amino compound. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | OC(CCN1CCCCC1)(c1ccccc1)C1CCCC1 |
Identifiers
| PDB | — |
| CAS-ID | 77-39-4 |
| RxCUI | 22037 |
| ChEMBL ID | CHEMBL1201227 |
| ChEBI ID | 59692 |
| PubChem CID | 2911 |
| DrugBank | DB00942 |
| UNII ID | 543567RFQQ (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 30 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,213 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more